EUCTR2009-011157-41-IT进行中(未招募)不适用
Efficacy and Safety assessment of T2345 unpreserved eyedrops versus Xalatan in ocular hypertensive or glaucomatous patients. - ND
ABORATORIES THEA0 个研究点目标入组 400 人开始时间: 2009年11月17日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients will be eligible for inclusion if all these criteria are respected: At Selection Visit: - Signed and dated informed consent, - Male or female aged from ≥ 18 to ≤ 90 years old, - Association of the following criteria for the eligible eye(s): - Chronic primary open angle glaucoma or chronic ocular hypertension - Already treated and controlled (since at least one year) by a monotherapy of Xalatan defined by: Stable IOP (≤ 18 mmHg), And Stable visual field defined by two available visual field: the penultimate visual field performed within the last 18 months the last visual field performed within the last 6 months and with an interval of at least 6 months between both visual fields. - Corneal thickness ≥ 510 Mm and ≤ 560 Mm. At Inclusion Visit: - IOP: IOP < 34 mmHg in BOTH eyes And IOP ≥ 22 mmHg in the eligible eye(s).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Ophthalmic non-inclusion criteria (in either eye) - Any secondary ocular hypertension. - Any severe glaucoma defined by study . - BCVA minor or equal to 1/10. - Aphakia. - Known history of ocular allergy and/or blepharitis and/or uveitis, traumatism, infection, ocular inflammation within the 3 months before the selection Visit, refractive surgery. - Severe dry eye. - Any abnormality preventing accurate assessment. Systemic/non ophthalmic non-inclusion criteria - General history: Non controlled asthma, Any medical or surgical history, disorder or disease and/or any complicating factor or structural abnormality, judged by the investigator to be incompatible with the study. - Known allergic hypersensitivity history to one of the components of the study medications or to test products. Specific non-inclusion criteria for women - Pregnancy, lactation, women without an effective method of contraception or women not hysterectomised, menopaused or surgically sterilized. Non-inclusion criteria related to general conditions - Inability of patient and/or relatives to understand the study procedures and thus inability to give informed consent. - Non compliant patient and/or relatives. - Participation in another clinical study within the last 3 months. - Already included once in this study. - Ward of court. - Patient not covered by the Social Security scheme when existing in the concerned country (NA in Italy).
研究者
相似试验
进行中(未招募)
1 期
Efficacy and Safety assessment of T2345 unpreserved eyedrops versus Xalatan® in ocular hypertensive or glaucomatous patients.Phase III study, multicentre, international, randomised, investigator-masked, 2 parallel groups, versus Reference product, in 400 evaluable patients treated during 3 months.The study population is suffering from glaucoma.MedDRA version: 9.1Level: LLTClassification code 10018304Term: GlaucomaMedDRA version: 9.1Level: PTClassification code 10018304Term: GlaucomaEUCTR2009-011157-41-FRlaboratoires théa400
进行中(未招募)
1 期
Efficacy and Safety assessment of T2345 unpreserved eyedrops versus Xalatan® in ocular hypertensive or glaucomatous patients.Phase III study, international, multicentre, randomised, investigator-masked, 2 parallel groups, versus reference product, in 360 evaluable patients treated for 3 months.EUCTR2009-011157-41-ESaboratoires Théa400
进行中(未招募)
不适用
Efficacy and Safety assessment of T2345 unpreserved eyedrops versus Xalatan® in ocular hypertensive or glaucomatous patients.Phase III study, international, multicentre, randomised, investigator-masked, 2 parallel groups, versus reference product, in 360 evaluable patients treated for 3 months.The study population will be suffering from open angle glaucoma or hypertension.MedDRA version: 12.0Level: LLTClassification code 10030348Term: Open angle glaucomaMedDRA version: 12.0Level: LLTClassification code 10030043Term: Ocular hypertensionEUCTR2009-011157-41-BEaboratoires Théa400
进行中(未招募)
不适用
Efficacy and Safety assessment of LT2345 unpreserved eye drops versus Xalatan in ocular hypertensive ou glaucomatous patients.PHase III study, international, multicentre, randomised, investigator masked, 2 parallel groups, versus reference product in 360 evaluable patents treated for 3 months.The study population is suffering from glaucoma.EUCTR2009-011157-41-PTaboratoires Thea400
已完成
2 期
Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular HypertensionPrimary Open Angle GlaucomaNCT01494753Laboratoires Thea30
